Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare read-only, open-world, idempotent, and non-destructive hints. The description adds substantial behavioral context beyond those: graceful degradation when GLEIF/OpenFIGI is unavailable, ambiguity resolution via figi_candidates, explicit labeling of identifier sources, the unresolved field, and internal cascading through multiple lookup endpoints. No contradictions with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense with valuable information, and it front-loads user phrasing examples and the core purpose. However, it is long and somewhat stream-of-consciousness, relying on nested parenthetical clauses. The length is largely justified by tool complexity, but restructuring into bullet points would aid scanning.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

This is a complex tool with no output schema, yet the description compensates thoroughly. It explains return contents (CIK, LEI, FIGI, figi_candidates, unresolved), edge cases (non-equity instruments, non-US issuers via ISIN-to-LEI), and failure behavior (EDGAR still returns if GLEIF/OpenFIGI is down). An agent has everything needed to use it correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Even though schema description coverage is 100%, the description adds significant meaning over the schema. It clarifies acceptable inputs for value: ticker, CIK, ISIN, or name for companies; brand or generic name for drugs. It also gives critical formatting guidance, such as passing only the issuer name rather than trailing security-class words, with a concrete example.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states the verb 'resolve' and the exact resource: user-spoken names to canonical/official identifiers. It opens with concrete example queries and explicitly distinguishes itself by producing identifiers 'other tools require as input', which clearly separates it from siblings like entity_profile and reverse.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'Use FIRST whenever you have a name but need an ID', giving a direct trigger condition. It also mentions that it replaces '2-3 manual lookups', implying it is the preferred entry point. However, it does not name specific alternative tools or state when not to use it, so exclusion guidance is missing.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation3/5

Several tools occupy adjacent territory—ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, and validate_claim all answer natural-language questions, and the Polymarket family has five overlapping analysis tools. The descriptions do a decent job of differentiating them, but an agent could still plausibly select the wrong variant in a mixed workflow.

Naming Consistency3/5

Most names follow a readable lowercase snake_case style, and there are coherent families like ask_pipeworx_*, polymarket_*, and pipeworx_*. However, conventions are mixed across the set—some are verb_noun (list_subscriptions, resolve_entity), some are bare verbs (forget, recall, reverse), and some are noun-phrase-only (entity_profile, recent_alerts)—so no single predictable pattern governs the whole server.

Tool Count2/5

33 tools is well past the 25+ threshold for a heavy tool surface, even accounting for the broad data-domain ambitions of the server. Many of these tools are meta-tools or thin variants of one another, so the set feels larger than necessary and imposes meaningful selection cost on an agent.

Completeness4/5

The server covers its apparent domain thoroughly: querying, grounded verification, deep research, entity resolution, profiles, comparisons, change tracking, claim validation, memory, subscriptions, and prediction-market analytics are all represented. Minor gaps exist—such as no direct tool for retrieving a raw pipeworx:// citation record and no account/auth flow—but agents can generally complete core workflows without dead ends.